Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylmethanesulfonic Acid SCHEMBL11217222 | 0.83 | CYP1A2 (0.64) | CYP1A2CYP2C9MEN1KMT2AALDH1A1 | |
| P-Xylene SCHEMBL3752326 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL2729317 | 0.82 | CYP1A2 (0.80) | CYP1A2CYP2C9ALDH1A1KDM4E | |
| Sulfuric Acid SCHEMBL31183034 | 0.82 | CYP1A2 (0.84) | CYP1A2CYP2C9ALDH1A1KDM4E | |
| SCHEMBL4015131 | 0.82 | CYP1A2 (0.61) | CYP1A2CYP2C9MEN1KMT2AALDH1A1 | |
| SCHEMBL5484470 | 0.81 | CYP1A2 (0.63) | CYP1A2CYP2C9MEN1KMT2AALDH1A1 | |
| SCHEMBL3459786 | 0.81 | CYP1A2 (0.65) | CYP1A2CYP2C9MEN1KMT2AALDH1A1 | |
| SCHEMBL19433083 | 0.80 | CYP1A2 (0.59) | CYP1A2CYP2C9MEN1KMT2ASMN1; SMN2 | |
| Ethylbenzene SCHEMBL7167647 | 0.80 | CYP1A2 (0.71) | CYP1A2CYP2C9MEN1KMT2AALDH1A1 | |
| SCHEMBL335423 | 0.79 | CYP1A2 (0.63) | CYP1A2CYP2C9MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012027033-A1 | COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| EP-0970100-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035977-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | NR2E3, NR4A1, NR4A3 | CYP1A2 99/4885CYP2C9 398/4885MEN1 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.